NCT01014091View on ClinicalTrials.gov

Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children

PHASE3TerminatedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

December 1, 2009

Primary Completion Date

January 14, 2011

Study Completion Date

January 14, 2011

Conditions

Influenza

Interventions

BIOLOGICAL

GSK pandemic vaccine GSK2340272A

2 intramuscular injections

Trial Locations (3)

1600

GSK Investigational Site, Prague

405 01

GSK Investigational Site, Děčín

532 03

GSK Investigational Site, Pardubice

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01014091 - Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children | Biotech Hunter | Biotech Hunter